Communicating accurate information about prescription drugs to healthcare professionals is not a discretionary act for pharmaceutical companies. The foreword to the Creation Guide opens by stating plainly that companies bear an obligation to transmit accurate information. That single sentence is the foundation on which every rule in the Guide rests. Why an obligation? Where does it come from? Grasping the answer is where reading the Guide must begin.
A Product Information Summary is simultaneously a promotional material and an information infrastructure on which healthcare professionals base prescribing and dispensing decisions. That dual nature sets the standards imposed on material production higher than ordinary advertising regulation.
01Promoting appropriate use — "selling" is not the starting point
The foreword defines the purpose of a Product Information Summary as "communicating accurate information about individual prescription drugs and promoting their appropriate use." The phrase "appropriate use" sets this purpose on a different axis from sales promotion.
Appropriate use means administering an approved drug for its approved indications, at the approved dosage, to the patients who need it, for no longer than necessary. The role of a Product Information Summary is to build the information environment that lets healthcare professionals make those judgments correctly. When materials tilt toward promotional exaggeration, prescribers make decisions on premises that do not reflect reality. The foreword places "promoting appropriate use" first in its statement of purpose precisely to make this structure explicit.
The idea that selling is sufficient is fundamentally incompatible with the aim of promoting appropriate use. Among the individual rules in the Guide, which are often read as advertising restrictions, the foreword's early statement of purpose carries structural weight that regulation alone cannot supply.
02Information asymmetry as the basis of the obligation
Physicians and pharmacists cannot read primary literature on every drug they handle. In practice, the information companies provide is the principal route through which healthcare professionals understand a product's efficacy and safety.
This is information asymmetry. Companies hold vast datasets accumulated from the earliest stages of development. Healthcare professionals have no independent means to verify the full picture. Inside this asymmetric structure, if companies select only favorable information to pass on, clinicians make judgments based on a distorted image. The consequences reach patients directly.
The foreword's use of the word "obligation" reflects the recognition that closing this asymmetry is the company's responsibility. Information provision is not a discretionary choice — it is a structural responsibility that the information-rich party owes to the information-poor party.
03An asymmetric obligation — disclosure includes unfavorable information
The duty to communicate accurate information does not apply only to information that is favorable to the company. Read in light of the foreword's spirit, safety information must be disclosed even when that information is unfavorable to the company.
This "asymmetric obligation" runs through the entire Guide as an undercurrent. Requirements that safety information be given equal or greater prominence than efficacy information, rules that important safety data appear in a form consistent with the package insert — all of these are structural safeguards against the temptation to show only what is convenient.
"Accurate" does not mean merely that the numbers are correct. Presenting only favorable data while suppressing inconvenient facts also violates the duty to communicate accurate information. The obligation imposed by the foreword reaches back to the stage of selection, before a single word is written.
In closing
The "obligation to communicate accurate information" is where the Creation Guide begins — and where every rule in it originates. Appropriate use as the governing purpose, structural responsibility arising from information asymmetry, disclosure that covers unfavorable facts as well as favorable ones: only when these three overlap does the full outline of the obligation come into view. The detailed prohibitions in later chapters are nothing more than this obligation translated into specific contexts.
Case studies — the "it isn't written, so…" mindset, and how each lands
The foreword's declaration of a "duty to transmit accurate information" and its stated purpose of "promoting appropriate use" leave no room for equating promotion with appropriate use whenever convenient. If information asymmetry grounds the duty, selectively disclosing only favorable data is not discharging that duty — it is hollowing it out. The four levels below trace that reasoning and its consequences.
GRAY 1 — Straying from the spirit (untouched by the wording, but against the foreword's spirit)
The scheme: "We have included comprehensive efficacy data, so we've met our obligation. Promoting appropriate use means making a good product widely known — promotion and appropriate use are entirely compatible."
Verdict: "Promoting appropriate use" means giving the right patient the right dose for the right duration — it sits on a different axis from "wider uptake." Volume of efficacy text cannot serve as a proxy for meeting the obligation. The correct approach is to prioritise accurate transmission of approved indications and dosage over sheer quantity of content.
GRAY 2 — Exploiting the gap (deliberately working a loophole to invite misreading)
The scheme: "If the duty is to close the information gap, then proactively sharing the favorable data only we possess is exactly how we discharge it. The unfavorable data are still under final internal review and cannot be released at this stage."
Verdict: The duty to close the information gap requires even-handed disclosure of all finalized data — favorable or not. Presenting only favorable findings under the banner of "closing the gap," while holding back finalized safety data as "under review," turns the duty's structure against itself. Completed safety data must be presented with equal priority.
GRAY 3 — Violating higher norms (arguably "not in the text," yet almost certainly out under the PMD Act, Fair Advertising Standards, and the JPMA Code)
The scheme: "The foreword doesn't explicitly say we must disclose unfavorable data. Exploratory safety findings aren't confirmed evidence, so there's no need to include them in the material."
Verdict: PMD Act Article 66 (prohibition of exaggerated advertising) and the Sales Information Provision Guidelines broadly prohibit selective disclosure that creates a false impression in healthcare professionals. "Not explicitly stated" is not an exemption at the statutory level. Exploratory safety data must be included, with its exploratory nature and source clearly identified.
BLACK — Breaching the explicit text (a plain violation of the provision itself)
The scheme: "Showing physicians the potential beyond the approved indication broadens their options and serves patients. The foreword's duty is ultimately for the patient — that reading justifies it."
Verdict: Including unapproved indications in a material constitutes the prohibited promotion of unapproved efficacy under PMD Act Article 68, and the Guidelines explicitly forbid content outside the approved scope. "For the patient's benefit" is not a defense against a statutory violation. No information about off-label use may appear in any promotional material.
Improper intent by implication — three scopes of "insinuating" without stating it
The duty to convey accurate information, declared in the Preamble, reaches down to the choice of a single word, the ordering of adjacent sentences, and the distribution of emphasis across the entire document. None of the following examples contains an explicit falsehood, yet each undermines the duty through implication.
Implication 1 — Local: carried in a single word or sentence
How it is built: "Narrow the grammatical subject of a results statement. Rather than 'the drug significantly improved outcomes,' write 'in the subgroup analysis of this trial, the drug showed a statistically significant difference' — folding the subgroup restriction inside the subject."
Intent that can be read: The failure of the primary endpoint on the full population recedes from view. A single subject-narrowing operation creates the impression that the subgroup result constitutes the trial's overall conclusion.
Verdict: Using a narrowed subject to conceal a primary-endpoint failure is a textbook example of misleading without lying. The Preamble's "do not mislead" obligation extends to word choice. When a favourable subgroup result is foregrounded, its relationship to the primary endpoint must be stated in the same sentence.
Implication 2 — Adjacent: read across neighboring clauses
How it is built: "State 'an extensive body of efficacy evidence has been accumulated' immediately followed by 'the safety profile has also been established,' while relegating safety details to a separate linked page."
Intent that can be read: Placing the two sentences side by side creates a holistic impression that both efficacy and safety are unproblematic. Readers who do not navigate to the linked page form the conviction 'safety confirmed' without seeing the specifics.
Verdict: Announcing 'safety established' while pushing the substance to a linked page is a hollow discharge of the duty to close the information asymmetry. The Preamble requires balanced delivery of both favourable and unfavourable information; a safety overview must be visible within the same field of view as the efficacy claims.
Implication 3 — Whole-context: arising from the document as a whole
How it is built: "Allocate ninety percent of the document to efficacy — with repeated sections on speed of onset, duration of effect, and dosing flexibility — and confine safety information to a boxed summary on the final page."
Intent that can be read: No individual statement is false, yet the cumulative effect of repetition and page-space allocation embeds the message 'this drug works; safety is a footnote.' The imbalance is structural rather than lexical.
Verdict: Proportional emphasis and repetition constitute evidence of intent that the Preamble's accuracy duty addresses. The obligation covers not only what is stated but how heavily each category of information is weighted. Efficacy and safety must be treated with substantively equivalent visibility throughout the document.